Friday, 13 October 2017

Neuren to conduct first phase 3 clinical trial for Rett Syndrome

(Rettsyndrome.org) Rettsyndrome.org is pleased to share that Neuren Pharmaceuticals, today, after meeting with the FDA, will conduct a Phase 3 clinical trial for trofinetide, a compound that shows great promise in the treatment of Rett syndrome, in children and adults. This critical Phase 3 trial will be the final clinical step before FDA approval to become a prescribable drug.

from EurekAlert! - Social and Behavioral Science http://ift.tt/2gCWKdh

No comments:

Post a Comment